Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BERLIN (Reuters) -Morphosys said its takeover by Novartis is still expected to close in the first half of this year, after a news report on a possible drug safety risk knocked the German biotechnology company's stock price on Monday. Morphosys' statement came after a report by specialist website STAT News, citing two people familiar with the matter, of a safety issue with its experimental drug pelabresib, which is being developed to treat myelofibrosis, a rare type of blood cancer affecting the bone marrow.